Sorafenib is an oral multikinase inhibitor that inhibits tumor growth and proliferation by interfering ... the aromatase inhibitors in patients with hormone receptor-positive MBC who have ...

As hormones change throughout the month ... Monis CN, Tetrokalashvili M. Menstrual cycle proliferative and follicular phase. In: StatPearls. StatPearls Publishing; 2024. Thiyagarajan DK ...

Madrigal Pharmaceuticals, X4 Pharmaceuticals and Day One Biopharmaceuticals secured their maiden approvals this year in ...

Endocrine cancers are a mixed group of diseases characterized by uncontrolled cellular proliferation of the hormone-producing ... report the results of a phase 2 trial of camrelizumab (anti ...

Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the ...

Patients with high-risk, hormone receptor (HR)-positive ... study results have shown. Primary results from the phase 2 SOLTI VALENTINE trial presented during the 2024 San Antonio Breast Cancer ...

Takeda has decided that there is a future for its aurora kinase A inhibitor alisertib after it failed a phase 3 trial in lymphoma ... alisertib has potential in hormone receptor-positive ...

It has now been 100 years since the first patient with diabetes received an injection of insulin, when Leonard Thomas, a 14-year-old boy, was treated with the hormone. The medical intervention was ...

Scientists explore how daily glucocorticoid signaling influences glioblastoma growth and synchronizes its circadian rhythms ...

The 1968 Treaty on the Non-Proliferation of Nuclear Weapons (NPT) is one of the most important and, with 191 signatory states, most comprehensive treaties of humankind. The NPT forms, together ...

Corticosteroids inhibit antigen presentation, cytokine production, and proliferation of lymphocytes ... are used to replace deficient endogenous hormones. In pharmacologic doses, corticosteroids ...